GlycoMimetics Inc. (NASDAQ: GLYC) Attends 31st Annual ROTH Conference
GlycoMimetics (NASDAQ: GLYC) is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly owned drug candidate, uproleselan, an E-selectin antagonist, is being evaluated in a pPhase 3 trial in relapsed/refractory AML. The FDA granted uproleselan breakthrough therapy designation for treatment of…







